OncoGenex To Present At The BioContact Quebec 2008 Annual Conference

    BOTHELL, WA and VANCOUVER, Oct. 1 /CNW/ - OncoGenex Pharmaceuticals, Inc
(NASDAQ:   OGXI) will present at the BioContact Quebec 2008 annual partnering
symposium on October 2 at 4:30 pm ET in the Salle Laval at the Chateau
Frontenac in Quebec City. OncoGenex' President and Chief Executive Officer,
Scott Cormack, will provide a corporate overview at the conference, including
a discussion of the Company's lead cancer drug candidate OGX-011 nearing
completion of multiple Phase 2 clinical trials.

    About OncoGenex Pharmaceuticals

    OncoGenex Pharmaceuticals is a biopharmaceutical company committed to the
development and commercialization of new cancer therapies that address unmet
needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with
each product candidate having a distinct mechanism of action and representing
a unique opportunity for cancer drug development. OGX-011, the lead candidate
currently completing five Phase 2 clinical studies in prostate, lung and
breast cancers, is designed to inhibit the production of a specific protein
associated with treatment resistance; OGX-427 and SN2310 are in Phase 1
clinical development; and CSP-9222 and OGX-225 are currently in pre-clinical
development. More information is available at www.oncogenex.com.

For further information:

For further information: OncoGenex Media and Investor Contact: Jason I.
Spark, Porter Novelli Life Sciences, (619) 849-6005,

Organization Profile

OncoGenex Pharmaceuticals, Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890